Buy Like Buffett
Watchlist

Johnson & Johnson

JNJ · Healthcare · $615.9B mkt cap · FY2025 filings · · Not rated ·

Not rated

Not rated
Share / Embed this score
Embed this result

We don't have enough comparable filing data to score at least four of the five filters for JNJ, so we don't publish a composite. Missing: returnsOnCapital, balanceSheet. No composite: 2 components abstained (returnsOnCapital: Not enough years of ROIC data to score returns on capital.; balanceSheet: Insufficient leverage/coverage inputs to score the balance sheet.).

20 years of fundamentals

The business, in plain English

Johnson & Johnson booked $94.2B of revenue in FY2025 in the Healthcare sector and kept 67.9% of it as gross profit — a high-margin business by that measure. After every other cost, 28.5% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $61.1B (FY2007) to $94.2B (FY2025) — about 2.4% a year compounded over 18 years.

ROIC is not available for the latest filed year, FY2025. Across the full 6-year measurable filed record, median ROIC was 21.9%.

The balance sheet carried $47.9B of total debt in FY2025 against $29.5B of owner earnings — roughly 1.6 years of owner earnings to retire it all.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2006–FY2025 · 20 fiscal years, normalized from JNJ’s SEC filings

Sales, as filed$94.2B FY2025
$0$50B$100B2006201320202025
Revenue kept after cost of goods67.9% FY2025
0%50%2006201320202025
Standard ROIC or separately labeled Operating ROICStandard ROIC 23.6% FY2014

Exact FY and FY-1 financing invested-capital inputs are required.. Current-year EBIT, tax expense, and non-zero pretax income are required for standard ROIC.

0%20%2006201320202025
Cash an owner could take out$29.5B FY2025
$0$20B$40B2006201320202025

The explained ROIC gaps have filed inputs but no meaningful positive invested-capital denominator. Other gaps mean the item is not in the filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How Johnson & Johnson makes its money

Johnson & Johnson's filing does not supply enough comparable lines for a truthful flow chart — here's what is filed:

Table alternative
Filed lineValue% of revenueSource
$94.2B100%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Cost of revenue$30.3B32%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
$63.9B68%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Income before tax$32.6B35%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Income tax$5.8B6%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
$26.8B28%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
· event Dec 28, 2025 · retrieved Oct 17, 2026 · annual-row source set

Flagship explainer

What Johnson & Johnson owns — and owes

Johnson & Johnson's filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed lineValue% of assetsSource
Total assets$199.2B100%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Cash and equivalents$19.7B10%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
$47.9B24%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Stockholders’ equity$81.5B41%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
· event Dec 28, 2025 · retrieved Oct 17, 2026 · annual-row source set

Flagship explainer

What drives Johnson & Johnson’s return on equity?

One or more filed inputs needed for the five-factor decomposition are unavailable.

DuPont source inputs
InputValueFiscal yearSource
Net income$26.8BFY2025
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Income before tax$32.6BFY2025
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Operating incomeUnavailableFY2025
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Revenue$94.2BFY2025
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Ending assets$199.2BFY2025
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Beginning assets$180.1BFY2024
  • 10-K · FY 2024Filing detailsAccession 0000200406-25-000038 · filed Feb 13, 2025
  • 10-K · FY 2024Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Ending equity$81.5BFY2025
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Beginning equity$71.5BFY2024
  • 10-K · FY 2024Filing detailsAccession 0000200406-25-000038 · filed Feb 13, 2025
  • 10-K · FY 2024Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Source: · event Dec 28, 2025 · retrieved Oct 17, 2026 · annual-row source set

Flagship explainer

Where Johnson & Johnson's cash went

Johnson & Johnson’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed lineValue% of cash from operationsSource
Cash from operations$24.5B100%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Depreciation and amortization$7.5B31%
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0000200406-26-000016 · filed Feb 11, 2026
· event Dec 28, 2025 · retrieved Oct 17, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding Johnson & Johnson

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

6 holding0 exited12 not holding18/19 resolved1 not retrieved

Named manager positions and quarter-over-quarter changes
ManagerReported positionQuarter-over-quarterFiling accession
Dodge & Cox20,947 shares$5.3M · 0% of eligible reported 13FUnchanged · 0 shares (0%)
Gardner Russo & Quinn1,112 shares$282415 · 0% of eligible reported 13FTrimmed · -192 shares (−15%)
Mairs & Power423,010 shares$107M · 1% of eligible reported 13FTrimmed · -154,580 shares (−27%)
Markel / Markel-Gayner610,800 shares$155M · 1% of eligible reported 13FUnchanged · 0 shares (0%)
Tweedy, Browne201,644 shares$51.2M · 4% of eligible reported 13FTrimmed · -17,846 shares (−8%)
Yacktman Asset Management1,259,977 shares$320M · 4% of eligible reported 13FAdded to position · +10,568 shares (1%)
Abrams CapitalNo position reportedNo position reported
Akre CapitalNo position reportedNo position reported
Baupost GroupNo position reportedNo position reported
Berkshire HathawayNo position reportedNo position reported
Brave Warrior AdvisorsNo position reportedNo position reported
First EagleNo position reportedNo position reported
FundsmithNo position reportedNo position reported
Gates Foundation TrustNo position reportedNo position reported
Oakmark / Harris AssociatesNo position reportedNo position reported
Polen CapitalNo position reportedNo position reported
Sequoia / Ruane CunniffNo position reportedNo position reported
Southeastern Asset ManagementNo position reportedNo position reported
Pershing SquareNot retrievedComparison not retrievedFiling not retrieved

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source:
37 SEC filings
  1. 13F-HR · Q1 2026Filing detailsAccession 0000813917-26-000038 · filed May 15, 2026
  2. 13F-HR · Q2 2026Filing detailsAccession 0000813917-26-000042 · filed Aug 14, 2026
  3. 13F-HR · Q1 2026Filing detailsAccession 0000860643-26-000003 · filed May 13, 2026
  4. 13F-HR · Q2 2026Filing detailsAccession 0000860643-26-000005 · filed Aug 13, 2026
  5. 13F-HR · Q1 2026Filing detailsAccession 0000905567-26-000002 · filed May 1, 2026
  6. 13F-HR · Q2 2026Filing detailsAccession 0000905567-26-000003 · filed Aug 11, 2026
  7. 13F-HR · Q1 2026Filing detailsAccession 0000919574-26-003132 · filed May 15, 2026
  8. 13F-HR · Q2 2026Filing detailsAccession 0000919574-26-005176 · filed Aug 14, 2026
  9. 13F-HR · Q1 2026Filing detailsAccession 0001061768-26-000007 · filed May 14, 2026
  10. 13F-HR · Q2 2026Filing detailsAccession 0001061768-26-000010 · filed Aug 13, 2026
  11. 13F-HR · Q1 2026Filing detailsAccession 0001096343-26-000044 · filed May 1, 2026
  12. 13F-HR · Q2 2026Filing detailsAccession 0001096343-26-000065 · filed Jul 31, 2026
  13. 13F-HR · Q1 2026Filing detailsAccession 0001104659-26-062592 · filed May 15, 2026
  14. 13F-HR · Q2 2026Filing detailsAccession 0001104659-26-097175 · filed Aug 14, 2026
  15. 13F-HR · Q1 2026Filing detailsAccession 0001112520-26-000009 · filed May 14, 2026
  16. 13F-HR · Q2 2026Filing detailsAccession 0001112520-26-000014 · filed Aug 14, 2026
  17. 13F-HR · Q1 2026Filing detailsAccession 0001172661-26-001819 · filed May 14, 2026
  18. 13F-HR · Q1 2026Filing detailsAccession 0001172661-26-001911 · filed May 14, 2026
  19. 13F-HR · Q1 2026Filing detailsAccession 0001172661-26-001966 · filed May 14, 2026
  20. 13F-HR · Q1 2026Filing detailsAccession 0001172661-26-002294 · filed May 15, 2026
  21. 13F-HR · Q2 2026Filing detailsAccession 0001172661-26-003035 · filed Aug 4, 2026
  22. 13F-HR · Q2 2026Filing detailsAccession 0001172661-26-003402 · filed Aug 13, 2026
  23. 13F-HR · Q2 2026Filing detailsAccession 0001172661-26-003496 · filed Aug 14, 2026
  24. 13F-HR · Q2 2026Filing detailsAccession 0001172661-26-003728 · filed Aug 14, 2026
  25. 13F-HR · Q1 2026Filing detailsAccession 0001193125-26-208439 · filed May 6, 2026
  26. 13F-HR · Q1 2026Filing detailsAccession 0001193125-26-223352 · filed May 14, 2026
  27. 13F-HR · Q1 2026Filing detailsAccession 0001193125-26-226661 · filed May 15, 2026
  28. 13F-HR · Q2 2026Filing detailsAccession 0001193125-26-340443 · filed Aug 7, 2026
  29. 13F-HR · Q2 2026Filing detailsAccession 0001193125-26-349535 · filed Aug 13, 2026
  30. 13F-HR · Q2 2026Filing detailsAccession 0001193125-26-352200 · filed Aug 14, 2026
  31. 13F-HR/A · Q1 2026 · Amendment RESTATEMENTFiling detailsAccession 0001325447-26-000018 · filed May 14, 2026
  32. 13F-HR · Q2 2026Filing detailsAccession 0001325447-26-000020 · filed Aug 5, 2026
  33. 13F-HR/A · Q2 2026 · Amendment NEW HOLDINGSFiling detailsAccession 0001325447-26-000033 · filed Aug 24, 2026
  34. 13F-HR · Q1 2026Filing detailsAccession 0001398344-26-009296 · filed May 15, 2026
  35. 13F-HR · Q2 2026Filing detailsAccession 0001398344-26-014641 · filed Aug 14, 2026
  36. 13F-HR · Q1 2026Filing detailsAccession 0001569205-26-000005 · filed May 15, 2026
  37. 13F-HR · Q2 2026Filing detailsAccession 0001569205-26-000012 · filed Aug 14, 2026
· event Jun 30, 2026 · retrieved Oct 17, 2026

Flagship explainer

What Johnson & Johnson insiders reported

Records still being gathered — partial as of retrieval Oct 17, 2026.

Partial coverage: the incomplete Form 4 walk cannot establish no activity, an activity date, or zero counts.

Moat Score history

33 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale

No composite readings yet — JNJ’s filings don’t give the engine enough comparable data to score, and we log that honestly instead of guessing a number.

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

  1. Normalizer upgraded unstamped (version unknown)moat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
  2. Methodology upgraded moat-index@2.0.0moat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
  3. Methodology upgraded moat-index@1.2.0moat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
  4. Methodology upgraded moat-index@1.1.0moat-index@1.2.0 — readings across versions aren’t comparedJul 17, 2026

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.

Records still being gathered — partial as of retrieval Oct 17, 2026.

6 filings were skipped because the SEC primary document returned 404; the omission is disclosed and aggregates are withheld.

Among the rows shown, A/F/M acquisition, payment or withholding, and exercise or conversion rows outnumber S sale rows (13 versus 9). The filing codes alone do not establish that every such row arose from a compensation plan.

Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.

InsiderShares owned afterDateFiling detail
Pinto Daniel EDirectorGrant, award, or other acquisition (A)Table II · Acquired · Deferred Share Units113.098$276.31$31,2502,445.177Sep 8, 2026
1 filed lot
  • Table II · Deferred Share Units: 113.098 shares at $276.31 · code A · owned after 2,445.177 ·
Woods Eugene A.DirectorGrant, award, or other acquisition (A)Table II · Acquired · Deferred Share Units135.717$276.31$37,5006,578.771Sep 8, 2026
1 filed lot
  • Table II · Deferred Share Units: 135.717 shares at $276.31 · code A · owned after 6,578.771 ·
HEWSON MARILLYN ADirectorGrant, award, or other acquisition (A)Table II · Acquired · Deferred Share Units180.956$276.31$50,00016,049.417Sep 8, 2026
1 filed lot
  • Table II · Deferred Share Units: 180.956 shares at $276.31 · code A · owned after 16,049.417 ·
Schmid TimothyEVP, WW Chair, MedTechExercise or conversion of derivative security (M)Table I · Acquired · Common Stock · 2 paired events33,597$144.9948$4,871,389See lot detailSep 2, 2026
2 filed lots
  • Table I · Common Stock: 11,070 shares at $131.94 · code M · owned after 36,517 · Paired event: 11,070 Employee Stock Options (Right to Buy) → 11,070 Common Stock ·
  • Table I · Common Stock: 22,527 shares at $151.41 · code M · owned after 47,974 · Paired event: 22,527 Employee Stock Options (Right to Buy) → 22,527 Common Stock ·
Schmid TimothyEVP, WW Chair, MedTechOpen-market or private sale (S)Table I · Disposed · Common Stock33,597$274.74$9,230,440See lot detailSep 2, 2026
2 filed lots
  • Table I · Common Stock: 11,070 shares at $274.74 · code S · owned after 25,447 ·
  • Table I · Common Stock: 22,527 shares at $274.74 · code S · owned after 25,447 ·
Schmid TimothyEVP, WW Chair, MedTechExercise or conversion of derivative security (M)Table II · Disposed · Employee Stock Options (Right to Buy) · 2 paired events33,597—Exercise or conversion of derivative security (M)—See lot detailSep 2, 2026
2 filed lots
  • Table II · Employee Stock Options (Right to Buy): 11,070 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 0 · Paired event: 11,070 Employee Stock Options (Right to Buy) → 11,070 Common Stock ·
  • Table II · Employee Stock Options (Right to Buy): 22,527 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 0 · Paired event: 22,527 Employee Stock Options (Right to Buy) → 22,527 Common Stock ·
Taubert Jennifer LEVP, WWC. Innovative MedicineExercise or conversion of derivative security (M)Table I · Acquired · Common Stock · 1 paired event15,000$115.67$1,735,050209,451.001Aug 17, 2026
1 filed lot
  • Table I · Common Stock: 15,000 shares at $115.67 · code M · owned after 209,451.001 · Paired event: 15,000 Employee Stock Options (Right to Buy) → 15,000 Common Stock ·
Taubert Jennifer LEVP, WWC. Innovative MedicineOpen-market or private sale (S)Table I · Disposed · Common Stock15,000$263.36$3,950,400194,451.001Aug 17, 2026
1 filed lot
  • Table I · Common Stock: 15,000 shares at $263.36 · code S · owned after 194,451.001 ·
Taubert Jennifer LEVP, WWC. Innovative MedicineExercise or conversion of derivative security (M)Table II · Disposed · Employee Stock Options (Right to Buy) · 1 paired event15,000—Exercise or conversion of derivative security (M)—28,712Aug 17, 2026
1 filed lot
  • Table II · Employee Stock Options (Right to Buy): 15,000 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 28,712 · Paired event: 15,000 Employee Stock Options (Right to Buy) → 15,000 Common Stock ·
Duato JoaquinDirector, CEO and Chairman of the BoardExercise or conversion of derivative security (M)Table I · Acquired · Common Stock · 1 paired event123,291$115.67$14,261,070399,258Aug 13, 2026
1 filed lot
  • Table I · Common Stock: 123,291 shares at $115.67 · code M · owned after 399,258 · Paired event: 123,291 Employee Stock Options (Right to Buy) → 123,291 Common Stock ·
Duato JoaquinDirector, CEO and Chairman of the BoardOpen-market or private sale (S)Table I · Disposed · Common Stock123,291$261.1701$32,199,927See lot detailAug 13, 2026
2 filed lots
  • Table I · Common Stock: 20,976 shares at $262.00 · code S · owned after 378,282 ·
  • Table I · Common Stock: 102,315 shares at $261.00 · code S · owned after 275,967 ·
Duato JoaquinDirector, CEO and Chairman of the BoardExercise or conversion of derivative security (M)Table II · Disposed · Employee Stock Options (Right to Buy) · 1 paired event123,291—Exercise or conversion of derivative security (M)—0Aug 13, 2026
1 filed lot
  • Table II · Employee Stock Options (Right to Buy): 123,291 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 0 · Paired event: 123,291 Employee Stock Options (Right to Buy) → 123,291 Common Stock ·
Forminard ElizabethEVP, Chief Legal OfficerExercise or conversion of derivative security (M)Table I · Acquired · Common Stock · 1 paired event9,344$131.94$1,232,84732,912Aug 6, 2026
1 filed lot
  • Table I · Common Stock: 9,344 shares at $131.94 · code M · owned after 32,912 · Paired event: 9,344 Employee Stock Options (Right to Buy) → 9,344 Common Stock ·
Forminard ElizabethEVP, Chief Legal OfficerOpen-market or private sale (S)Table I · Disposed · Common Stock15,918$257.0021$4,090,960See lot detailAug 6, 2026
2 filed lots
  • Table I · Common Stock: 9,344 shares at $257.755 · code S · owned after 23,568 ·
  • Table I · Common Stock: 6,574 shares at $255.932 · code S · owned after 16,994 ·
Forminard ElizabethEVP, Chief Legal OfficerExercise or conversion of derivative security (M)Table II · Disposed · Employee Stock Options (Right to Buy) · 1 paired event9,344—Exercise or conversion of derivative security (M)—0Aug 6, 2026
1 filed lot
  • Table II · Employee Stock Options (Right to Buy): 9,344 shares at — (Exercise or conversion of derivative security (M)) · code M · owned after 0 · Paired event: 9,344 Employee Stock Options (Right to Buy) → 9,344 Common Stock ·
Duato JoaquinDirector, CEO and Chairman of the BoardOpen-market or private sale (S)Table I · Disposed · Common Stock48,480$258.1479$12,515,010See lot detailAug 5, 2026
2 filed lots
  • Table I · Common Stock: 41,957 shares at $258.056 · code S · owned after 282,490 ·
  • Table I · Common Stock: 6,523 shares at $258.739 · code S · owned after 275,967 ·

Source-event as of . Retrieved .

Track record

How Johnson & Johnson’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.

Point-in-time scores 2011–2025, one methodology version · reconstructed from filings on file each Dec 31 — never with hindsight

Point-in-time Moat Score (dot colored by tier)Indexed price (total-return (dividends reinvested))Rated Wide-moat that year

How to read this: each dot is what the engine would have scored JNJ on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.

0406080100WideNarrowShallowNo moatPoint-in-time Moat Score100200500Indexed price · log scale (2012 = 100)201120142017202020232026

Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The price path is a total-return (dividends reinvested) index built from the same data the forward returns use; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.

What followed, in the years it rated Wide

In the 9 years JNJ rated Wide-moat (2011, 2014, 2015, 2016, 2017, 2020, 2021, 2022 and 2023), the median forward total return that followed — measured only after each year’s filings were public — was:

  • 1 year 7% vs the S&P 500’s 15% (price basis) · median over 9 years
  • 3 years 32% vs the S&P 500’s 34% (price basis) · median over 8 years
  • 5 years 65% vs the S&P 500’s 80% (price basis) · median over 6 years

These are medians computed from the data, not a claim about any one year. The company figures are total returns (dividends reinvested); the S&P 500 is the price-only ^GSPC index, which excludes dividends and so understates the index — the gap flatters the company. A quality rating is not a return forecast, and past returns don’t predict future ones. Educational only, not investment advice.

Healthcare context

Not ranked — JNJ doesn’t have enough comparable filing data for a composite score, so we don’t place it on the board.

Healthcare leaders by Moat Score

  1. #1IDXX IDEXX LABORATORIES INC /DE96.2Wide moat
  2. #2LLY ELI LILLY AND COMPANY94.3Wide moat
  3. #3RMD ResMed Inc.93.8Wide moat

All Healthcare companies on the Index →

Common questions about JNJ

Does Johnson & Johnson have an economic moat?
We don't publish a Moat Score for Johnson & Johnson (JNJ): its SEC filings don't provide enough comparable data to score at least four of the five filters, and the Index records each gap rather than a guessed number. Missing inputs: returns on capital, balance-sheet safety.
Is JNJ trading below the conservative owner-earnings estimate?
The value if growth stopped today — a zero-growth baseline — is $113.49 per share. It capitalizes normalized owner earnings at a 9% rate and assumes 0% growth. Versus a recent price of $255.56, that is 125% above value if growth stopped today. The model also publishes a capped-growth comparison, but the zero-growth estimate is the cautious baseline. It assumes trailing owner earnings persist and is unreliable for declining businesses. This is an educational estimate from primary SEC filings, not intrinsic value as a fact or investment advice.
How has JNJ's Moat Score changed over time?
The record logs 33 readings since Jul 17, 2026, none with a composite — JNJ hasn't had enough comparable filing data to score. No tier changes on record yet. (Methodology or normalizer upgrades on Jul 17, 2026, Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell JNJ. See the disclaimer.